Experimental biomarkers in heart failure: an update

References

• Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91(5), 606–612 (2005).
   PubMed Web of Science ®Google Scholar
• Maeda K, Tsutamoto T, Wada A et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol. 36(5), 1587–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Yu CM, Sanderson JE. Plasma brain natriuretic peptide – an independent predictor of cardiovascular mortality in acute heart failure. Eur. J. Heart Fail. 1(1), 59–65 (1999).
   PubMed Web of Science ®Google Scholar
• Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 358(20), 2148–2159 (2008).
   PubMed Web of Science ®Google Scholar
• Anand IS, Latini R, Florea VG et al. ; Val-HeFT Investigators. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112(10), 1428–1434 (2005).
   PubMed Web of Science ®Google Scholar
• Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud AP. Inflammation and long-term mortality in acute congestive heart failure. Am. Heart J. 151(4), 845–850 (2006).
   PubMed Web of Science ®Google Scholar
• Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16), 2055–2059 (2001).
   PubMed Web of Science ®Google Scholar
• Miettinen KH, Lassus J, Harjola VP et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur. J. Heart Fail. 10(4), 396–403 (2008).
   PubMed Web of Science ®Google Scholar
• Matsubara J, Sugiyama S, Nozaki T et al. Pentraxin-3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J. Am. Coll. Cardiol. 57(7), 861–869 (2011).
   PubMed Web of Science ®Google Scholar
• Ishino M, Takeishi Y, Niizeki T et al. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX-3. Circ. J. 72(11), 1800–1805 (2008).
   PubMed Web of Science ®Google Scholar
• Anand IS, Kempf T, Rector TS et al. Serial measurement of growth–differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122(14), 1387–1395 (2010).
   PubMed Web of Science ®Google Scholar
• Milo-Cotter O, Cotter-Davison B, Lombardi C et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology 119(2), 96–105 (2011).
   PubMedGoogle Scholar
• Matsumoto M, Tsujino T, Lee-Kawabata M et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine 49(3), 264–268 (2010).
   PubMedGoogle Scholar
• Suzuki S, Takeishi Y, Niizeki T et al. Pentraxin-3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am. Heart J. 155(1), 75–81 (2008).
   PubMed Web of Science ®Google Scholar
• Kempf T, von Haehling S, Peter T et al. Prognostic utility of growth–differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(11), 1054–1060 (2007).
   PubMed Web of Science ®Google Scholar
• Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W. CA-125 and its relation to cardiac function. Am. Heart J. 137(6), 1044–1049 (1999).
   PubMed Web of Science ®Google Scholar
• Sikaris KA. CA125 – a test with a change of heart. Heart. Lung Circ. 20(10), 634–640 (2011).
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Nikolaou M, Cohen Solal A. Tumour biomarkers in heart failure: is there a role for CA-125? Eur. J. Heart Fail. 13(6), 579–583 (2011).
   PubMedGoogle Scholar
• Faggiano P, D’Aloia A, Brentana L et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur. J. Heart Fail. 7(1), 57–61 (2005).
   PubMedGoogle Scholar
• D’Aloia A, Faggiano P, Aurigemma G et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J. Am. Coll. Cardiol. 41(10), 1805–1811 (2003).
   PubMed Web of Science ®Google Scholar
• Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur. J. Heart Fail. 10(6), 556–559 (2008).
   PubMedGoogle Scholar
• Núñez J, Sanchis J, Bodí V et al. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur. Heart J. 31(14), 1752–1763 (2010).
   PubMed Web of Science ®Google Scholar
• Vondráková D, Málek F, Oštádal P et al. Correlation of NT-proBNP, proANP and novel biomarkers: copeptin and proadrenomedullin with LVEF and NYHA in patients with ischemic CHF, nonischemic CHF and arterial hypertension. Int. J. Cardiol. 150(3), 343–344 (2011).
   PubMedGoogle Scholar
• Vergaro G, Emdin M, Iervasi A et al. Prognostic value of plasma renin activity in heart failure. Am. J. Cardiol. 108(2), 246–251 (2011).
   PubMedGoogle Scholar
• Richards AM, Doughty R, Nicholls MG et al. ; Australia–New Zealand Heart Failure Group. Plasma N-terminal probrain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia–New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 37(7), 1781–1787 (2001).
   PubMed Web of Science ®Google Scholar
• Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 54(4), 752–756 (2008).
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Carbonieri E et al. ; GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-Heart Failure (GISSI-HF) trial. Eur. J. Heart Fail. 12(4), 338–347 (2010).
   PubMed Web of Science ®Google Scholar
• Røsjø H, Masson S, Latini R et al. ; GISSI-HF Investigators. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur. J. Heart Fail. 12(6), 549–556 (2010).
   PubMed Web of Science ®Google Scholar
• Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J. 28(9), 1117–1127 (2007).
   PubMed Web of Science ®Google Scholar
• Ceconi C, Ferrari R, Bachetti T et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23(12), 967–974 (2002).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Gegenhuber A, Struck J et al. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta 400(1–2), 91–96 (2009).
   PubMedGoogle Scholar
• Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am. J. Med. 119(7 Suppl. 1), S47–S53 (2006).
   PubMed Web of Science ®Google Scholar
• Khan SQ, Dhillon OS, O’Brien RJ et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115(16), 2103–2110 (2007).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311(13), 819–823 (1984).
   PubMed Web of Science ®Google Scholar
• Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 87(Suppl. 6), VI40–VI48 (1993).
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106(23), 2961–2966 (2002).
   PubMed Web of Science ®Google Scholar
• Ky B, French B, McCloskey K et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 4(2), 180–187 (2011).
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5), 721–726 (2003).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL et al. ; MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54(23), 2174–2179 (2009).
   PubMed Web of Science ®Google Scholar
• Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52(18), 1458–1465 (2008).
   PubMed Web of Science ®Google Scholar
• von Haehling S, Jankowska EA, Morgenthaler NG et al. Comparison of midregional proatrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(20), 1973–1980 (2007).
   PubMedGoogle Scholar
• Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of proatrial natriuretic peptide. Circ. Heart Fail. 4(2), 114–120 (2011).
   PubMed Web of Science ®Google Scholar
• McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109(8), 1004–1009 (2004).
   PubMed Web of Science ®Google Scholar
• Rudiger A, Harjola VP, Müller A et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur. J. Heart Fail. 7(4), 662–670 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J. Am. Soc. Nephrol. 20(11), 2305–2313 (2009).
   PubMed Web of Science ®Google Scholar
• Lassus J, Harjola VP, Sund R et al. ; for the FINN-AKVA Study group. Prognostic value of cystatin-C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur. Heart J. 28(15), 1841–1847 (2007).
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Januzzi JL Jr, Boronat-Garcia M et al. b-trace protein and cystatin-C as predictors of long-term outcomes in patients with acute heart failure. J. Am. Coll. Cardiol. 57(7), 849–858 (2011).
   PubMed Web of Science ®Google Scholar
• Naruse H, Ishii J, Kawai T et al. Cystatin-C in acute heart failure without advanced renal impairment. Am. J. Med. 122(6), 566–573 (2009).
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Boronat-Garcia M, Albaladejo-Otón MD et al. Complementary prognostic value of cystatin-C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am. J. Cardiol. 103(12), 1753–1759 (2009).
   PubMed Web of Science ®Google Scholar
• Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I et al. Prognostic value of cystatin-C on admission in heart failure with preserved ejection fraction. J. Card. Fail. 17(1), 31–38 (2011).
   PubMed Web of Science ®Google Scholar
• Damman K, van der Harst P, Smilde TD et al. Use of cystatin-C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 98(4), 319–324 (2012).
   PubMed Web of Science ®Google Scholar
• Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur. Heart J. 32(21), 2705–2712 (2011).
   PubMed Web of Science ®Google Scholar
• Nymo SH, Ueland T, Askevold ET et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. J. Intern. Med. 271(5), 436–443 (2012).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Mueller C, Fitzgerald R et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur. J. Heart Fail. 13(8), 846–851 (2011).
   PubMed Web of Science ®Google Scholar
• Alvelos M, Lourenço P, Dias C et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int. J. Cardiol. (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K. β-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin. Chem. 45(4), 567–568 (1999).
   PubMed Web of Science ®Google Scholar
• Keith M, Geranmayegan A, Sole MJ et al. Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol. 31(6), 1352–1356 (1998).
   PubMed Web of Science ®Google Scholar
• Ide T, Tsutsui H, Hayashidani S et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ. Res. 88(5), 529–535 (2001).
   PubMed Web of Science ®Google Scholar
• Zimmet JM, Hare JM. Nitroso–redox interactions in the cardiovascular system. Circulation 114(14), 1531–1544 (2006).
   PubMed Web of Science ®Google Scholar
• Tang WH, Brennan ML, Philip K et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am. J. Cardiol. 98(6), 796–799 (2006).
   PubMed Web of Science ®Google Scholar
• Polidori MC, Praticó D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J. Card. Fail. 10(4), 334–338 (2004).
   PubMed Web of Science ®Google Scholar
• Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. (Lond.) 555(Pt 3), 589–606 (2004).
   Google Scholar
• Watanabe E, Matsuda N, Shiga T et al. Significance of 8-hydroxy-2′-deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy. J. Card. Fail. 12(7), 527–532 (2006).
   PubMedGoogle Scholar
• Kono Y, Nakamura K, Kimura H et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ. J. 70(8), 1001–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Susa T, Tanaka T et al. Urinary 8-hydroxy-2′-deoxyguanosine reflects symptomatic status and severity of systolic dysfunction in patients with chronic heart failure. Eur. J. Heart Fail. 13(1), 29–36 (2011).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Shishido T, Ishino M et al. 8-Hydroxy-2′-deoxyguanosine is a prognostic mediator for cardiac event. Eur. J. Clin. Invest. 41(7), 759–766 (2011).
   PubMedGoogle Scholar
• Rogowski O, Shnizer S, Wolff R, Lewis BS, Amir O. Increased serum levels of oxidative stress are associated with hospital readmissions due to acute heart failure. Cardiology 118(1), 33–37 (2011).
   PubMed Web of Science ®Google Scholar
• Cicoira M, Rossi A, Bonapace S et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail. 10(5), 403–411 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi R, Negishi K, Watanabe A et al. Serum syndecan-4 is a novel biomarker for patients with chronic heart failure. J. Cardiol. 57(3), 325–332 (2011).
   PubMedGoogle Scholar
• Krum H, Elsik M, Schneider HG et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ. Heart Fail. 4(5), 561–568 (2011).
   PubMedGoogle Scholar
• Kanoupakis EM, Manios EG, Kallergis EM et al. Serum markers of collagen turnover predict future shocks in implantable cardioverter–defibrillator recipients with dilated cardiomyopathy on optimal treatment. J. Am. Coll. Cardiol. 55(24), 2753–2759 (2010).
   PubMedGoogle Scholar
• Chatzikyriakou SV, Tziakas DN, Chalikias GK et al. Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy. Eur. J. Pharmacol. 628(1–3), 164–170 (2010).
   PubMed Web of Science ®Google Scholar
• Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ. Res. 96(5), 488–500 (2005).
   PubMed Web of Science ®Google Scholar
• Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation 112(20), 3122–3130 (2005).
   PubMed Web of Science ®Google Scholar
• Chen WJ, Lin KH, Lee YS. Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-α1(I) collagen gene expression by thyroid hormone receptor. Mol. Cell. Endocrinol. 162(1–2), 45–55 (2000).
   PubMedGoogle Scholar
• Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation 122(4), 385–393 (2010).
   PubMed Web of Science ®Google Scholar
• Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am. J. Med. 118(2), 132–136 (2005).
   PubMed Web of Science ®Google Scholar
• Passino C, Pingitore A, Landi P et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J. Card. Fail. 15(1), 35–40 (2009).
   PubMed Web of Science ®Google Scholar
• Iacoviello M, Guida P, Guastamacchia E et al. Prognostic role of subclinical hypothyroidism in chronic heart failure outpatients. Curr. Pharm. Des. 14(26), 2686–2692 (2008).
   PubMed Web of Science ®Google Scholar
• Cardinale D, Cipolla CM. Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. Herz 36(4), 325–332 (2011).
   PubMedGoogle Scholar
• Dispenzieri A, Gertz MA, Kyle RA et al. Serum cardiac troponins and N-terminal probrain natriuretic peptide: a staging system for primary systemic amyloidosis. J. Clin. Oncol. 22(18), 3751–3757 (2004).
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand IS et al. ; Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116(11), 1242–1249 (2007).
   PubMed Web of Science ®Google Scholar
• Masson S, Anand I, Favero C et al. ; Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca–Heart Failure (GISSI-HF) Investigators. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 125(2), 280–288 (2012).
   PubMed Web of Science ®Google Scholar
• Jungbauer CG, Riedlinger J, Buchner S et al. High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide. Clin. Chem. Lab. Med. 49(11), 1899–1906 (2011).
   PubMed Web of Science ®Google Scholar
• Peacock WF 4th, De Marco T, Fonarow GC et al. ; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med. 358(20), 2117–2126 (2008).
   PubMed Web of Science ®Google Scholar
• Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur. J. Heart Fail. 13(1), 37–42 (2011).
   PubMed Web of Science ®Google Scholar
• Ilva T, Lassus J, Siirilä-Waris K et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur. J. Heart Fail. 10(8), 772–779 (2008).
   PubMed Web of Science ®Google Scholar
• Dinh W, Nickl W, Füth R et al. High sensitive troponin T and heart fatty acid-binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study. BMC Cardiovasc. Disord. 11, 41 (2011).
   PubMedGoogle Scholar
• O’Connor CM, Fiuzat M, Lombardi C et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. Circ. Heart Fail. 4(6), 724–732 (2011).
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ. J. 72(1), 109–114 (2008).
   PubMed Web of Science ®Google Scholar
• Margulies KB, Bednarik DP, Dries DL. Genomics, transcriptional profiling, and heart failure. J. Am. Coll. Cardiol. 53(19), 1752–1759 (2009).
   PubMedGoogle Scholar
• Margulies KB. MicroRNAs as novel myocardial biomarkers. Clin. Chem. 55(11), 1897–1899 (2009).
   PubMedGoogle Scholar
• Vanburen P, Ma J, Chao S, Mueller E, Schneider DJ, Liew CC. Blood gene expression signatures associate with heart failure outcomes. Physiol. Genomics 43(8), 392–397 (2011).
   PubMedGoogle Scholar
• Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113(11), 1424–1433 (2006).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Buser P, Rickli H et al. ; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301(4), 383–392 (2009).
   PubMed Web of Science ®Google Scholar